Daniel Rosenberg
Daniel Rosenberg is an analyst at Paradigm Capital, specializing in the technology and video infrastructure sectors. He recently expressed a positive view on Haivision Systems Inc., noting improvements in profitability and operational efficiency despite facing revenue challenges due to macro uncertainty.
Not in the pool (under ¢1).
Recent news mentions
Daniel Rosenberg is the director of the colon cancer prevention program at the Carole and Ray Neag Comprehensive Cancer Center in Connecticut.
Study shows walnuts may lower colon cancer risk and reduce inflammation
United States· 2025-05-20
Daniel Rosenberg is a researcher at the University of Connecticut and co-author of the study on the health benefits of walnuts.
Nucile, aliați neașteptați în lupta împotriva inflamației și cancerului de colon. Doza zilnică ce îți protejează inima și colonul
Romania· 2025-05-11
Daniel Rosenberg bumped his Sabio Holdings Inc. target to $1.50 with a 'buy' rating.
Wednesday’s analyst upgrades and downgrades
Canada· 2025-03-19
Daniel Rosenberg thinks Haivision Systems Inc. is 'operating more efficiently and is more profitable compared to last year.'
Monday’s analyst upgrades and downgradesCanada· 2025-03-17
